A lower BATF2 mRNA expression was detectable in serum of patients with chronic myeloid leukemia (CML) compared to healthy controls, and BATF2 downregulation-induced BCR-ABL inhibition was critical in the occurrence and development of CML (Huang et al., 2011). This evidence concerns the gene BATF2 and chronic myelogenous leukemia, BCR-ABL1 positive.